Pharmaceutical Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X

Learning from tragedy: safety and dosing in first-in-human trials

The Rennes clinical trial disaster in January last year highlights the dangers posed by first-in-human trials of high-risk drug candidates, with dosing strategies coming under the spotlight. What makes early-stage trials go wrong, and how can dosing protocols be improved to minimise health risks to trial participants?

Go Top